• Beacon Endoscopic (Newton, Massachusetts) reported the limited market launch of the BNX System, its fine needle aspiration platform for use in endoscopic ultrasound (EUS) and endoscopic bronchial ultrasound. The BNX System uses a delivery system that loads and unloads FNA needles of varying sizes. Another feature of the BNX design is that it automatically sheaths all needles with a shield during needle removal. Initially, Beacon will work with 20 large endoscopy centers in the U.S. to gain insights from the top gastroenterologists as to training techniques and clinical positioning.

• Cambridge Heart (Tewksbury, Massachusetts), a maker of non-invasive diagnostic tests for cardiac disease, said that results of a prospective, 155-patient trial reinforce the value of the Microvolt T-Wave Alternans (MTWA) test as a predictor of life-threatening heart rhythms and Sudden Cardiac Death (SCD). The results were published this in the journal Kardiologia Polska. Patients underwent MTWA testing using Cambridge Heart's analytic spectral method prior to implantation and were followed for major arrhythmic cardiac events (MACE) including SCD or intractable life-threatening arrhythmias requiring ablation or heart transplant. At a median follow-up time of 22 months, patients with an abnormal MTWA test were 11 times more likely to experience a major arrhythmic cardiac event than patients with a normal MTWA result. The negative predictive value was 98.6%, indicating that patients with a normal or negative MTWA test are at very low risk of experiencing life-threatening arrhythmias.

No Comments